- Home
- SD vs PRTA Comparison
SD vs PRTA Comparison
Compare SD & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | PRTA |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.9M | 538.3M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | SD | PRTA |
|---|---|---|
| Price | $16.81 | $8.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.86 |
| AVG Volume (30 Days) | 305.7K | ★ 490.1K |
| Earning Date | 03-09-2026 | 02-19-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 40.92 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $155,930,000.00 | $11,786,000.00 |
| Revenue This Year | $31.95 | N/A |
| Revenue Next Year | $16.82 | $1,183.79 |
| P/E Ratio | $9.01 | ★ N/A |
| Revenue Growth | ★ 29.68 | N/A |
| 52 Week Low | $8.81 | $4.32 |
| 52 Week High | $16.61 | $16.67 |
Technical Indicators
Market Signals| Indicator | SD | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 67.05 | 44.64 |
| Support Level | $15.69 | $8.23 |
| Resistance Level | $16.61 | $9.05 |
| Average True Range (ATR) | 0.51 | 0.53 |
| MACD | 0.09 | -0.07 |
| Stochastic Oscillator | 83.17 | 28.26 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.